Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
Scientists from the Gray Faculty of Medical & Health Sciences at Tel Aviv University introduced an innovative gene therapy method to treat impairments in hearing and balance caused by inner ...
Adeno-associated viruses (AAVs) have emerged in recent years as a crucial tool in clinical gene therapies, offering low pathogenicity and long-lived gene expression in target cells. AAVs are simple ...
Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock ...
Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...
About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback